The average cost of developing a new drug is estimated to be in the billions and takes 10-15 years. Drug repurposing aims at retargeting existing drugs or drug candidates for the treatment of medical conditions that they were not originally developed, or licensed, to treat. With the advent of big data, computational biology and network biology, scientists have realized that many existing drugs can be efficacious in the treatment of diseases with similar molecular profiles. Since the safety of these drugs has already been evaluated in the clinic, this approach dramatically cuts the cost of drug development and speeds up the time to get a drug from bench to bedside. It also promises to improve the treatment of rare diseases, in which the enormous investment required for drug development is economically not viable.
“Our consortium aims to create a European infrastructure to get the right drug to the right patient”, says group leader Jörg Menche. “We bring together stakeholders from different fields to provide a platform for all matters related to drug repurposing, such as identifying a potential purpose for a novel compound, connecting an existing drug to a new indication, addressing intellectual property rights, or conducting targeted clinical trials”. Jörg’s group will work at the scientific core of the consortium: “We will use our molecular network expertise to identify the actual molecular modules that are being perturbed in a given disease, and then try to match this information with existing compounds and approved drugs”, explains Jörg Menche.
Jörg also teaches ‘Network Medicine’ in the Master’s course in Molecular Precision Medicine, a joint program of the Medical University of Vienna and the University of Vienna. The goal of the course is to teach students the molecular basis of pathogenesis and how this information can be leveraged in treatments. For many diseases, the underlying mechanisms are poorly understood and treatment regimens often only tackle the symptoms. With its focus on connecting the molecular mechanisms that underlie diseases with appropriate medication, drug repurposing may also pave the way for personalized and precision medicine. “In our course, Jörg teaches how mathematics and computation can be used to disentangle complex interactions in the treatment of disease”, says Curriculum Director Thomas Leonard. “Jörg’s participation in an EU-wide effort to integrate knowledge and expertise for drug repurposing can only profit our students”.
Nutrient-regulated control of lysosome function by signaling lipid conversion
Shedding Light on the Dark Side of Terrestrial Ecosystems: Assessing Biogeochemical Processes in Soils
Protein homeostasis and lifelong cell maintenance
Dissecting the turgor sensing mechanisms in the blast fungus Magnaporthe oryzae
Pikobodies: What does it take to bioengineer NLR immune receptor-nanobody fusions
When all is lost? Measuring historical signals
Gene regulatory mechanisms governing human development, evolution and variation
Regulation of Cerebral Cortex Morphogenesis by Migrating Cells
Phage therapy for treating bacterial infections: a double-edged sword
Suckers and segments of the octopus arm
Using the house mouse radiation to study the rapid evolution of genes and genetic processes
CRISPR jumps ahead: mechanistic insights into CRISPR-associated transposons
SLiMs and SHelMs: Decoding how short linear and helical motifs direct PPP specificity to direct signaling
Title to be announced
Visualising mitotic chromosomes and nuclear dynamics by correlative light and electron microscopy
Enigmatic evolutionary origin and multipotency of the neural crest cells - major drivers of vertebrate evolution
Engineered nanocarriers for imaging of small proteins by CryoEM
Bacterial cell envelope homeostasis at the (post)transcriptional level
Title to be announced
Hydrologic extremes alter mechanisms and pathways of carbon export from mountainous floodplain soils
Dissecting post-transcriptional gene expression regulation in humans and viruses
Polyploidy and rediploidisation in stressful times
Prdm9 control of meiotic synapsis of homologs in intersubspecific hybrids
Title to be announced
RNA virus from museum specimens
Programmed DNA double-strand breaks during meiosis: Mechanism and evolution
Title to be announced